OBJECTIVE: To evaluate the effectiveness and tolerability of omega-3 polyunsaturated fatty acid (PUFA) supplementation for treatment of trait anxiety among adolescent females with restrictive anorexia nervosa (AN). METHOD: A pilot double-blind, placebo-controlled randomized trial of adolescent females with AN (N = 24) entering Partial Hospitalization Program (PHP) from January 2015 to February 2016. Participants were randomized to four daily PUFA (2,120 mg eicosapentaenoicacid/600 mg docosohexaenoic acid) or placebo capsules for 12 weeks. A 9-item questionnaire of side effect frequency assessed medication tolerability. The Beck Anxiety Inventory-Trait measured anxiety at baseline, 6, and 12 weeks. Linear mixed models evaluated associations between randomization group and study outcomes. Twenty-two and 18 participants completed 6 and 12 weeks of data collection, respectively. RESULTS:Medication side effect scores were low and were not significantly different between randomization groups at Week 6 (p = .20) or 12 (p = .41). Mean trait anxiety score significantly (p < .01) decreased from baseline to 12 weeks in both groups, and the rate of change over the course of time did not differ between omega-3PUFA and placebo groups (p = .55). CONCLUSION:Omega-3PUFA supplementation was well tolerated in adolescent females with AN. Although power to detect differences was limited, we found no evidence that omega-3PUFA benefited anxiety beyond nutritional restoration.
RCT Entities:
OBJECTIVE: To evaluate the effectiveness and tolerability of omega-3 polyunsaturated fatty acid (PUFA) supplementation for treatment of trait anxiety among adolescent females with restrictive anorexia nervosa (AN). METHOD: A pilot double-blind, placebo-controlled randomized trial of adolescent females with AN (N = 24) entering Partial Hospitalization Program (PHP) from January 2015 to February 2016. Participants were randomized to four daily PUFA (2,120 mg eicosapentaenoic acid/600 mg docosohexaenoic acid) or placebo capsules for 12 weeks. A 9-item questionnaire of side effect frequency assessed medication tolerability. The Beck Anxiety Inventory-Trait measured anxiety at baseline, 6, and 12 weeks. Linear mixed models evaluated associations between randomization group and study outcomes. Twenty-two and 18 participants completed 6 and 12 weeks of data collection, respectively. RESULTS: Medication side effect scores were low and were not significantly different between randomization groups at Week 6 (p = .20) or 12 (p = .41). Mean trait anxiety score significantly (p < .01) decreased from baseline to 12 weeks in both groups, and the rate of change over the course of time did not differ between omega-3 PUFA and placebo groups (p = .55). CONCLUSION:Omega-3 PUFA supplementation was well tolerated in adolescent females with AN. Although power to detect differences was limited, we found no evidence that omega-3 PUFA benefited anxiety beyond nutritional restoration.
Authors: Nicole C Barbarich; Claire W McConaha; Katherine A Halmi; Kelly Gendall; Suzanne R Sunday; Jill Gaskill; Maria La Via; Guido K Frank; Sarah Brooks; Katherine H Plotnicov; Walter H Kaye Journal: Int J Eat Disord Date: 2004-01 Impact factor: 4.861
Authors: Augustine Osman; Joseph Hoffman; Francisco X Barrios; Beverly A Kopper; Joseph L Breitenstein; Susan K Hahn Journal: J Clin Psychol Date: 2002-04
Authors: Janice K Kiecolt-Glaser; Martha A Belury; Rebecca Andridge; William B Malarkey; Ronald Glaser Journal: Brain Behav Immun Date: 2011-07-19 Impact factor: 7.217
Authors: William A Carlezon; Stephen D Mague; Aimee M Parow; Andrew L Stoll; Bruce M Cohen; Perry F Renshaw Journal: Biol Psychiatry Date: 2005-02-15 Impact factor: 13.382
Authors: Sara Ulfvebrand; Andreas Birgegård; Claes Norring; Louise Högdahl; Yvonne von Hausswolff-Juhlin Journal: Psychiatry Res Date: 2015-09-15 Impact factor: 3.222
Authors: Jochen Seitz; Beate Herpertz-Dahlmann; Lara Keller; Astrid Dempfle; Brigitte Dahmen; Samira Schreiber; Roger A H Adan; Nadia Andrea Andreani; Unna N Danner; Albrecht Eisert; Sergueï Fetissov; Florian Ph S Fischmeister; Andreas Karwautz; Kerstin Konrad; Karlijn L Kooij; Stefanie Trinh; Benny van der Vijgh; Annemarie A van Elburg; Michael Zeiler; John Baines Journal: Trials Date: 2022-07-05 Impact factor: 2.728
Authors: Kathrin Cohen Kadosh; Melissa Basso; Paul Knytl; Nicola Johnstone; Jennifer Y F Lau; Glenn R Gibson Journal: Transl Psychiatry Date: 2021-06-16 Impact factor: 6.222